HBV Mutation Detail Information

> M204V Search Result

Mutation Information

Mutation Site	M204V
Mutation Type	Amino acid level
Gene/Protein/Region Type	RT
Combined Mutation	rt.M204V+rt.L180M;rt.M204V+rt.L180M+rt.V173L
Relevant Drug	lamivudine (LAM);tenofovir (TDF);adefovir (ADV)

Literature Information

PubMed PMID	21871497
Published Year	2011
Journal	Antiviral research
Title	The main hepatitis B virus (HBV) mutants resistant to nucleoside analogs are susceptible in vitro to non-nucleoside inhibitors of HBV replication.
Author	Billioud G,Pichoud C,Puerstinger G,Neyts J,Zoulim F
Evidence	HepG2 stable cell line permanently expressing wild type (WT) HBV or the main HBV mutants resistant to lamivudine and/or adefovir (rtL180M+rtM204V, rtV173L+rtL180M+rtM204V, rtM204I, rtL180M+rtM204I, rtN236T, rtA181V, rtA181V+rtN236T, rtA181T, rtA181T+rtN236T) were treated with AT-61, AT-130 or BAY-41 4109.

Contents
Description

Mutation Information Note

Gene/Protein/Region Type: Virus Gene (e.g. LMP-1) or Virus Protein (e.g. Rep 68) or Virus Region (e.g. S, X)

Literature Information Note

Evidence: sentence contains this mutation information in the citation